Efficacy of Hepatitis B Immune Globulin for Prevention of Perinatal Transmission of the Hepatitis B Virus Carrier State: Final Report of a Randomized Double‐Blind, Placebo‐Controlled Trial
R. Palmer Beasley, Lu‐Yu Hwang, Cladd E. Stevens, Chia‐Chin Lin, Fon‐Jou Hsieh, Kwei‐Yu Wang, Tsu‐Shen Sun, Wolf Szmuness – 1 January 1983 – A randomized double‐blind, placebo‐controlled efficacy trial of hepatitis B immune globulin (HBIG) for prevention of the mother‐to‐infant transmitted HBsAg carrier state was conducted in Taiwan where the carrier rate in the general population is 15 to 20%. HBIG was given immediately after birth to infants of e antigen positive HBsAg carrier mothers, and all infants were followed for at least 15 months.